XXVI Congress

85 days

19 hours

41 mins

Our Partners

We are very grateful for support from our partners, please click on any logos below to head to their website.

If you would like to see your logo here, head over to our Sponsorship Guide page to find out how we can work together!

Diamond

Merck

As part of Merck KGaA, Darmstadt, Germany, BioReliance® Services is a key component of the life science services portfolio and the leading provider of contract services in the biopharmaceutical industry. BioReliance’s comprehensive and integrated services support every phase of the testing, development and manufacturing process. With locations worldwide, BioReliance offers more than 1,000 tests and complementary services related to biologics safety testing and specialized toxicology. Our clients include the world’s top producers of traditional pharmaceuticals, medical devices and chemicals, as well as biopharmaceuticals

Oxford Biomedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. The Company has built a sector leading lentiviral vector delivery platform (LentiVector®) through which it continues to develops in vivo and ex vivo gene & gene-modified therapies products both in-house and with partners. Oxford BioMedica has entered into a number of key partnerships, including with Novartis, Sanofi, GSK, Green Cross Lab Cell and Immune Design. Oxford BioMedica has world class facilities and capabilities encompassing the full range of GMP manufacturing and analytical activities to support pre-clinical, research and bioprocessing development through to GMP production and supply of clinical trial materials.  The production activities are focussed on the manufacture of lentiviral vectors from human cell lines, both in adherent and large scale serum free suspension culture. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 230 people.

Platinum

Bluebird Bio

Bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s bone marrow into which a healthy version of the disease causing gene is inserted.

MeiraGTx

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders.

We are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). We are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. Our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

 

Intellia

Intellia Therapeutics is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia was named as one of the top 10 biotech start-ups by Nature Biotechnology. In September 2015, Intellia was named a “Fierce 15” biotech company by FierceBiotech

Adverum

Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline and is leveraging its next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. 

Rocket

Rocket Pharma is a clinical-stage gene therapy company with a platform approach for the treatment of patients with high-unmet need rare diseases. We leverage lentiviral and AAV transduction strategies towards first-in-class programs.  Hallmarks of Rocket’s vision include: 1) a high threshold for the selection of quality programs, 2) leverage of deep industry know-how through a world-class team (Novartis Cell & Gene, Bluebird, BMS, others) and manufacturing partnerships (MolMed, PCT, others) and 3) a laser focus on optimizing gene therapy product parameters through a seasoned scientific approach that de-risks programs as they enter clinical trials.

Fond National Suisse de la Recherche

The SNSF promotes scientific research in Switzerland. It promotes the international competitiveness and integration of this research as well as its capacity to solve problems. It pays particular attention to the promotion of young researchers.

Sarepta

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates and is proud to support the 2018 AANEM Annual Meeting. For more information about Sarepta.

Gold

Genethon

Genethon, created by AFM-Telethon, has the mission to make innovative  gene therapy treatments available to patients affected with rare genetic diseases. To meet this challenge Genethon has assembled the technical and human resources needed to accelerate the medical application of scientific discoveries arising from fundamental research. Strong translational research programs engage multi-disciplinary teams and are supported by a first rate technological platform and cGMP facility

The pipeline of Genethon includes products currently in international clinical trials and at preclinical stages, for muscular dystrophies, immune deficiencies, blood, ocular and liver diseases. These products are developed either with Genethon as sponsor, or in partnership with private companies and academic institutions.

Editas

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies. The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, and Huntington’s disease.

Molmed

MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes antitumour therapeutics in clinical and preclinical development: Zalmoxis® (TK), a cell-based therapy; NGR-hTNF, a novel therapeutic agent for solid tumours; CAR-CD44v6, an immuno-gene therapy project; MolMed also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trials activities. MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana

Brammer Bio

Brammer Bio is a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies.  Brammer offers end-to-end CDMO services from Phase I/II in Florida through commercial manufacturing in Massachusetts.  Brammer Bio provides clinical and commercial supply of viral vectors for in vivo gene and ex vivo modified-cell based therapies, process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health.  The Brammer team consists of extraordinary employees focused exclusively on serving the gene therapy needs of clients and their patients. We are Helping to Cure.®

Maxcyte

MaxCyte's non-viral delivery platform allows for engineering of nearly all cell types, including human primary cells, with any molecule, at any scale for use in drug discovery and development, biomanufacturing, gene editing, cell therapy, and immuno-oncology. Its consistency and minimal cell disturbance facilitate rapid, clinical and commercial grade cell engineering.

Audentes

Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  Audentes is currently developing four product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

KCT

KCT is newly formed research center in Kuopio, Finland. We provide high quality basic and translational research. Professional team and laboratories with cutting edge devices are providing scientific know-how and modern technologies to develop advanced therapies. We undertake science in collaboration with academic groups all over the world. Link to FinVector's GMP manufacturing, quality and regulatory teams ensures product path from research to patients.
 

Gene Therapy Centre Austria

Available Gene therapy relevant development and manufacturing capabilities and capacities can hardly support the strong growth of gene therapy product development activities across the globe. Long process development times and low yield manufacturing processes slow down product development and add significant costs and risks to the development and licensure of gene therapy products.
The Gene Therapy Center Austria (GTCA) covers all steps from vector to GMP production (200L, 500L, and 1000L) until early stage commercial including a broad range of AAV specific analytical methods.
GTCA’s one-stop-shop concept is based on Shire’s proprietary AAV technology platform. The GTCA has successfully demonstrated lot-to-lot consistency and scalability across multiple programs.
Our partners benefit from our 30+ year experience in development, approval and global supply of complex biologics which reduces product development risks for our development partners and for our CMO clients.
 

Silver

uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases

BioNTech

EXPERTS IN CELL AND GENE THERAPY MANUFACTURING: BioNTech Innovative Manufacturing Services (IMFS) is a Contract Development and Manufacturing Organisation specialized in the industrialization of cell and gene therapy products (viral vectors, cells and ivt mRNA). Based on extensive expertise in scientific, technical and regulatory prerequisites, we develop and manufacture your products in a safe and cost-efficient way in our state-of-the-art GMP facility. We offer a complete service spectrum from process development through clinical trial to in-market supply. All services are fully integrated and supervised by our QA department ensuring efficient and compliant manufacturing.

Abeona

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB- 101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV- FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing its proprietary vector platform, AIM™, for next generation product candidates.

Paragon

Paragon Bioservices is an award-winning Contract Development & Manufacturing Organization (CDMO). Our aim is to build strong client partnerships focusing on transformative technologies, including oncology, immunotherapies (CAR-T cell therapies and oncolytic viruses), new generation vaccines (VLPs) and gene therapies (AAV). Paragon’s cGMP facilities include microbial and mammalian suites, aseptic fil-finish and full-segregated virus facilities.
Responsibility to our clients, a passion for science and our collective need to contribute to better public heath—is what keeps us motivated and excited about the work that we perform. We are driven by our commitment to provide exceptional quality scientific performance and customer service.
With over 25 years in the business, Paragon’s scientists, engineers, quality systems personnel and project managers have many years of experience working with biologics—from research and process development services to GMP manufacturing for clinical trials and eventual commercial launch.
 

Delphi Genetics

Delphi Genetics develops innovative technologies and provides services in (i) production of plasmid DNA (pDNA) and recombinant proteins and (ii) antibody development. 
The Staby® technology was developed to replace the antibiotic-resistance gene by a selection system that uses two natural bacterial genes. The technology is already used successfully for industrial productions in E. coliof recombinant proteins and pDNA to achieve higher yields using antibiotics-free media. The Staby® technology meets the regulatory guidelines for the use of plasmid DNA in gene therapy (naked plasmid DNA and for the production of recombinant viruses). Additionally, the technology guarantees plasmid stability during production scale-up and increases production efficiency.
The company developed a complete single-use process for GMP-compliant productions of plasmid DNA and collaborates on projects at all stages of development from R&D to clinical phases with or without technology. The company has its own facilities for productions in R&D, High Quality and GMP.
 
 

Novasep

Novasep: services and technologies for life science and chemical industries

Novasep is a leading international provider of services for the Life Science industry, based on specialized technologies. The Group is recognized for its expertise in the field of molecule production and purification.

Selecta Biosciences, Inc

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by mitigating unwanted immune responses.

Yposkesi

Yposkesi is the largest European CDMO for gene therapy vector manufacturing. Created in November 2016 in Corbeil Essonnes (France) as a spin off from the world-class gene therapy pioneer Genethon, Yposkesi provides a full-service offer covering BioProcess development (USP & DSP), from small/pilot to large production scale,analytical development, GMP manufacturing of clinical lots of lentiviral vectors and regulatory support.
Its current facility consists in a 50,000 sq ft building, operating 4 manufacturing suites for bulk drug substance, and 2 Fill & Finish suites.  This capacity will be expanded in 2021 with a large scale facility (50,000 sq ft) equipped with 2,000L bioreactors, designed for commercial production and compliant to EMA and FDA.  Capitalizing on more than 25 years of expertise, Yposkesi significantly invests in innovation in bioprocessing to cost-effectively deliver on high quality projects.